SWOG clinical trial number
SWOG-9104
Evaluation of Doxorubicin/Vinblastine Combined with Inhibitors (Trifluoperazine/Verapamil) of P-Glycoprotein in Patients with Advanced Renal Cell Carcinoma, Phase II
Closed
Phase
Accrual
65%
Published
Abbreviated Title
Evaluation of Doxorubicin/Vinblastine Combined with Inhibitors (Trifluoperazine/Verapamil) of P-Glycoprotein in Patients with Advanced Renal Cell Carcinoma, Phase II
Activated
09/01/1992
Closed
09/01/1994
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
1997
Phase II evaluation of doxorubicin/vinblastine combined wtih inhibitors (trifluoperazine/verapamil) of p-glycoprotein in patients with advanced renal carcinoma.
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase